Skip to content

Aclaris Therapeutics, Inc.

ACRS· NasdaqCore metricsCIK 1557746

Pharmaceutical preparations552 peers

Last sale
Nov 12, 2026 · -7.72%
Market cap
$635.24M
158.61M shares
Filings
874
$1.48M
Q3 2026−58.2% FY25 yoy
-$18.51M
Q3 2026N/M FY25 yoy
-$21.34M
Q3 2026N/M FY25 yoy
-$62.16M
Q3 2026derivedN/M FY25 yoy
-$0.12
Q3 2026N/M FY25 yoy
$20.39M
Q3 2026−18.8% FY25 yoy
$635.24M
—
99.2×
3.8×
-11.86%
—

Twelve months to Sep 30, 2026 · derived

Price

$4.01+74.13%+$1.71past year
Nov 12, 2026 · IEX last sale
Figure
Range
IEX last saleClose of recordAs traded

Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Financials

Revenue

$7.83MFY 2025
$31.25M0FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025
PeriodEndedValueKindSource trail
FY 20252025-12-31$7,826,000reported
FY 20242024-12-31$18,720,000reported
FY 20232023-12-31$31,249,000reported
FY 20222022-12-31$29,752,000reported
FY 20212021-12-31$6,761,000reported
FY 20202020-12-31$6,482,000reported
FY 20192019-12-31$4,227,000reported
FY 20182018-12-31$6,151,000 revisedreported
FY 20172017-12-31$1,683,000reported

Segments

Revenue by Segments, FY2018 to FY2025FY2018Contract Research Segment · FY2018 · $13.14MTherapeutics Segment · FY2018 · $1.50MFY2019Contract Research Segment · FY2019 · $16.82MFY2020Contract Research Segment · FY2020 · $13.32MTherapeutics Segment · FY2020 · $696.00KFY2021Contract Research Segment · FY2021 · $5.83MTherapeutics Segment · FY2021 · $932.00KFY2022Contract Research Segment · FY2022 · $4.40MTherapeutics Segment · FY2022 · $25.36MFY2023Contract Research Segment · FY2023 · $3.04MTherapeutics Segment · FY2023 · $28.21MFY2024Single reportable segment · FY2024 · $18.72MContract Research Segment · FY2024 · $2.54MTherapeutics Segment · FY2024 · $16.18MFY2025Single reportable segment · FY2025 · $7.83M
LineFY2025ShareChange
Single reportable segment$7.83M100%−58.2%
Contract Research Segment———
Therapeutics Segment———
Total$7.83M

From the 10-K filed Feb 26, 2026ACRS

Pharmaceutical preparations

Aclaris Therapeutics, Inc. is the 177th largest of the 553 covered companies the SEC files under this code, by revenue. SIC 2834

Peers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.

Aclaris Therapeutics, Inc. · CIK 1557746 · Engraved from SEC EDGAR